Aligning animal models with clinical epilepsy: Where to begin?

Advances in Experimental Medicine and Biology

Volumn 813, Issue , 2014, Pages 243-251

  Harward, Stephen C ^a   McNamara, James O ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Animal models; Epilepsy; Fragile X; Temporal lobe epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; ETHOSUXIMIDE; FRAGILE X MENTAL RETARDATION PROTEIN; KAINIC ACID; PILOCARPINE; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; LORAZEPAM;

ABSENCE; ARTICLE; CONSTRUCT VALIDITY; DISEASE MODEL; DRUG EFFICACY; DRUG RESPONSE; EPILEPSY; EPILEPTIC STATE; FACE VALIDITY; FRAGILE X SYNDROME; GENE MUTATION; HUMAN; KNOCKOUT MOUSE; NEUROSURGERY; NONHUMAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RETT SYNDROME; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TEMPORAL LOBE EPILEPSY; AMYGDALOID NUCLEUS; CFTR GENE; CLINICAL FEATURE; DISEASE SEVERITY; EPILEPTOGENESIS; GENE; GENETIC VARIABILITY; HISTOPATHOLOGY; MESIAL TEMPORAL LOBE EPILEPSY; MOLECULAR DYNAMICS; MOLECULAR GENETICS; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN BINDING; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SYNAPSE;

ANIMALS; EPILEPSY; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL;

EID: 84934438760     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-94-17-8914-1_19     Document Type: Article

References (43)

1. Annegers JF, Hauser WA, Shirts SB, Kurland LT (1987) Factors prognostic of unprovoked seizures after febrile convulsions. N Engl J Med 316:493-498
2. Ashley C, Wilkinson K, Reines D, Warren S (1993) FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262:563-566
3. Ben-Ari Y, Tremblay E, Ottersen OP (1980) Injections of kainic acid into the amygdaloid c omplex of the rat: an electrographic, clinical and histological study in relation to the pathology of epilepsy. Neuroscience 5:515-528
4. Bhakar AL, Dolen G, Bear MF (2012) The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 35:417-443
5. Chadman KK, Yang M, Crawley JN (2009) Criteria for validating mouse models of psychiatric diseases. Am J Med Genet B Neuropscyhiatr Genet 150B:1-11
6. Chudley AE, Hagerman RJ (1987) Fragile X syndrome. J Pediatr 110:821-831
7. Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P (2001) De novo mutations in the sodium-channel gene SCN1A causes severe myoclonic epilepsy of infancy. Am J Hum G enet 68:1327-1332
8. Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Warren ST (2009) Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 85:503-514
9. Cornish K, Sudhalter V, Turk J (2004) Attention and language in fragile X. Ment Retard Dev Disabil Res Rev 10:11-16
10. Devys D, Lutz Y, Rouyer N, Bellocq JP, Mandel JL (1993) The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X permutation. Nat Genet 4:335-340
11. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF (2007) Correction of fragile X syndrome in mice. Neuron 56:955-962
12. Dudek EF, Clark S, Williams PA, Grabenstatter HL (2006) Kainate-induced status epilepticus: a chronic model of acquired epilepsy. In: Pitkanen A, Schwartzkroin PA, Moshe SL (eds) Models of seizures and epilepsy. Elsevier, Burlingto n, pp 415-432
13. Dunleavy M, Shinoda S, Schindler C, Ewart C, Dolan R, Gobbo OL, Kerskens CM, Henshall DC (2010) Experimental neonatal status epilepticus and the development of temporal lobe e pilepsy with unilateral hippocampal sclerosis. Am J Pathol 176:330-342
14. Dutch-Belgian Fragile X Consort (1994) Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78:23-33
15. French JA, Williamson PD, Thadani VM, Darey TM, Mattson RH, Spencer SS, Spencer DD (1993) Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination . Ann Neurol 34:774-780
16. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC (2013) Ethosuximide, valproic acid, and lamotrigine in chil dhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia 54:141-155
17. Guilbault C Saeed Z Downey GP Radzioch D 2007 Cystic fibrosis mouse models Am J Respir Cell Mol Biol 36 1-7
18. Hagberg B, Aicardi J, Dias K, Ramos O (1983) A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol 14:471-479
19. Hesdorffer DC, Shinnar S, Lewis DV, Moshe SL, Nordli DR Jr, Pellock JM, MacFall J, Shinnar RC, Masur D, Frank LM, Epstein LG, Litherland C, Seinf eld S, Bello JA, Chan S, Bagiella E, Sun S (2012) FEBSTAT study team. Design and phenomenology of the FEBSTAT study. Epilepsia 53:1471-1480
20. Jimenez-Mateos EM, Engel T, Merino-Serrais P, McKiernan RC, Tanaka K, Mouri G, Sano T, O'Tuathaigh C, Waddington JL, Prenter S, Delanty N, Farrell MA, O'Brien DF, Conroy RM, Stallings RL, DeFelipe J, Henshall DC (2012) Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med 18:1087-1094
21. Krueger DD, Bear MF (2011) Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62:411-429
22. Laggerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A, Fischer U (2001) Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet 10:329-338
23. Liu G, Gu B, He XP, Joshi RB, Wackerle HD, Rodriguiz RM, Wetsel WC, McNamara JO (2013) Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy. Neuron 79:31-38
24. Lubs HA (1969) A marker X chromoso me. Am J Hum Genet 21:231-244
25. Luby M, Spencer DD, Kim JH, deLanerolle N, McCarthy G (1995) Hippocampal MRI volumetrics and temporal lobe substrates in medial temporal lobe epilepsy. Magn Res on Imaging 13:1065-1071
26. Martin JP, Bell J (1943) A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry 6:154-157
27. Mouri G, Jimenez-Mateos E, Engel T, Dunleavy M, Hatazaki S, Paucard A, Matsushima S, Taki W, Henshall DC (2008) Unilateral hippocampal CA3-predominant damage and short latency epileptogenesis after intra-amygdala microinjection of kainic acid in mice. Brain Res 1213:140-151
28. Nance MA, Hauser WA, Anderson VE (1997) Genetic diseases associated with epilepsy. In: Engel J, Pedley TA (eds) Epilepsy: a comprehensive textbook, 1st edn. Lippincott-Raven, Philadelphia, pp 197-209
29. Neul JL, Kaufmann WE, Glaze DG, Chirstodoulou J, Clarke AJ, Bahi-Buisson N, Leonard H, Bailey ME, Schanen NC, Zappella M, Renieri A, Huppke P, Percy AK, RettSearch Consortium (2010) Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 68:944-950
30. Penagarikano O, Mulle JG, Warren ST (2007) The pathophysiology of fragile X syndrome. Annu Rev Genomics Hum Genet 8:109-129
31. Pieretti M, Zhang FP, Fu Y-H, Warren ST, Oostra BA, Caskey CT, Nelson DL (1991) Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66:817-822
32. Putnam TJ, Merritt HH (1937) Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 85:525-526
33. Raol YH, Brooks-Kayal AR (2012) Experimental models of seizures and epilepsies. Prog Mol Biol Transl Sci 105:57-82
34. Reid CA, Berkovic SF, Petrou S (2009) Mechanisms of inherited epilepsies. Prog Neurobiol 87:41-57
35. Sarkisian MR (2001) Overview of the current animal models for human seizure and epileptic disorders. Epilepsy Behav 2:201-216
36. Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G (1993) The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74:291-298
37. Tsai MH, Chuang YC, Chang HW, Chang WN, Lai SL, Huang CR, Tsai NW, Wang HC, Lin YJ, Lu CH (2009) Factors predictive of outcome in patients with de novo status epilepticus. Q J Med 1 02:57-62
38. VanLandingham KE Heinz ER Cavazos JE Lewis DV 1998 Magnetic resonance imaging evidence of hippocampal injury after prolonged focal febrile convulsions Ann Neurol 43 413-426
39. Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DPA, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, Eussen BE, van Ommen GJB, Blonden LAJ, Riggins GJ, Chas tain JL, Kunst CB, Galjaard H, Caskey CT, Nelson DL, Oostra BA, Warren ST (1991) Identification of a gene ( FMR-1 ) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragil e X syndrome. Cell 65:905-914
40. Weiler IJ, Greenough WT (1993) Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc Natl Acad Sci U S A 90:7168-7171
41. Wieser HG (2004) ILAE Commission report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 45:695-714
42. Wilkinson KD, Keene JD, Darnell RB, Warren ST (2001 ) Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107:477-488
43. Williamson PD, French JA, Thadani VM, Kim JM, Nove lly RA, Spencer SS, Spencer DD, Mattson RH (1993) Characteristics of medial temporal lobe epilepsy: II. Interictal and ictal scalp electroencephalography, neuropsychological testing, neuroimaging, surgical results, and pathology. Ann Neurol 34:781-787